title: Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.
abstract: BACKGROUND
  The Prouts Neck Meetings on Prostate Cancer began in 1985 through the efforts of the Organ Systems Branch of the National Cancer Institute to stimulate new research and focused around specific questions in prostate tumorigenesis and therapy.
  
  
  METHODS
  These meetings were think tanks, composed of around 75 individuals, and divided equally between young investigators and senior investigators. Over the years, many new concepts related to prostate cancer resulted from these meetings and the prostate cancer community has sorely missed them since the last one in 2007.
  
  
  RESULTS
  We report here the first of a new series of meetings. The 2013 meeting focused on defining how the field of treatment for metastatic prostate cancer needs to evolve to impact survival and was entitled: "Beyond AR: New Approaches to Treating Metastatic Prostate Cancer." As castrate resistant prostate cancers escape second generation anti-androgen agents, three phenotypes/genotypes of CRPC appear to be increasing in prevalence and remain resistant to treatment: NeuroEndocrine Prostate Cancer, Persistent AR-Dependent Prostate Cancer, and Androgen Receptor Pathway Independent Prostate Cancer.
  
  
  CONCLUSIONS
  It is clear that new treatment paradigms need to be developed for this diverse group of diseases. The Prouts Neck 2013 Meeting on Prostate Cancer helped to frame the current state of the field and jumpstart ideas for new avenues of treatment.
authors.affiliation: Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland; Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland.
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Pienta
authors.forename: Guneet
authors.initials: G
authors.lastname: Walia
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Simons
authors.forename: Howard R
authors.initials: HR
authors.lastname: Soule
mesh_terms: D000818:Animals; D003226:Congresses as Topic; D006801:Humans; D007167:Immunotherapy; D008297:Male; D054547:National Cancer Institute (U.S.); D009362:Neoplasm Metastasis / Q000628:therapy*; D014411:Neoplastic Stem Cells; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy; D011944:Receptors, Androgen; D059016:Tumor Microenvironment; D014481:United States
chemical_list: D011944:Receptors, Androgen
keywords: diagnostics; metastases; therapeutics; treatment resistance; tumor microenvironment